These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3489072)

  • 21. Mesencephalic dopamine neurons become less sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity during development in vitro.
    Danias P; Nicklas WJ; Ofori S; Shen J; Mytilineou C
    J Neurochem; 1989 Oct; 53(4):1149-55. PubMed ID: 2788714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine.
    Fuller RW; Hemrick-Luecke SK; Robertson DW
    Biochem Pharmacol; 1988 Sep; 37(17):3343-7. PubMed ID: 3135812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.
    Sun CJ; Johannessen JN; Gessner W; Namura I; Singhaniyom W; Brossi A; Chiueh CC
    J Neural Transm; 1988; 74(2):75-86. PubMed ID: 3266233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals.
    Hollinden GE; Sanchez-Ramos JR; Sick TJ; Rosenthal M
    Brain Res; 1988 Dec; 475(2):283-90. PubMed ID: 3265070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.
    Fries DS; de Vries J; Hazelhoff B; Horn AS
    J Med Chem; 1986 Mar; 29(3):424-7. PubMed ID: 3485197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MPTP causes a non-reversible depression of synaptic transmission in mouse neostriatal brain slice.
    Wilson JA; Wilson JS; Weight FF
    Brain Res; 1986 Mar; 368(2):357-60. PubMed ID: 3008929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Mytilineou C; Cohen G
    J Neurochem; 1985 Dec; 45(6):1951-3. PubMed ID: 3932598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
    Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
    Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ascorbic acid and striatal transport of [3H] 1-methyl-4-phenylpyridine (MPP+) and [3H] dopamine.
    Debler EA; Hashim A; Lajtha A; Sershen H
    Life Sci; 1988; 42(25):2553-9. PubMed ID: 3260319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
    Melamed E; Rosenthal J; Cohen O; Globus M; Uzzan A
    Eur J Pharmacol; 1985 Oct; 116(1-2):179-81. PubMed ID: 3876943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum.
    Donnan GA; Kaczmarczyk SJ; Rowe PJ; Figdor R; Mendelsohn FA
    J Neurol Sci; 1986 Jun; 74(1):111-9. PubMed ID: 3487620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Astrocytes as a primary locus for the conversion MPTP into MPP+.
    Brooks WJ; Jarvis MF; Wagner GC
    J Neural Transm; 1989; 76(1):1-12. PubMed ID: 2785159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.
    Vyas I; Heikkila RE; Nicklas WJ
    J Neurochem; 1986 May; 46(5):1501-7. PubMed ID: 3485701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral and biochemical changes following acute administration of MPTP and MPP+.
    Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H
    Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice.
    Sundström E; Goldstein M; Jonsson G
    Eur J Pharmacol; 1986 Nov; 131(2-3):289-92. PubMed ID: 3493159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the release of 1-methyl-4-phenylpyridinium (MPP+) from rat striatal neurons in vitro.
    Keller HH; Da Prada M
    Eur J Pharmacol; 1985 Dec; 119(3):247-50. PubMed ID: 3879221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromelanin: a role in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Life Sci; 1987 Feb; 40(8):705-12. PubMed ID: 2880274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
    Melamed E; Rosenthal J; Globus M; Cohen O; Uzzan A
    Brain Res; 1985 Sep; 342(2):401-4. PubMed ID: 3876139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methylamphetamine and MPTP.
    Rollema H; De Vries JB; Westerink BH; Van Putten FM; Horn AS
    Eur J Pharmacol; 1986 Dec; 132(1):65-9. PubMed ID: 3102260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.